- Home
- CRON vs EVMN Comparison
CRON vs EVMN Comparison
Compare CRON & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRON | EVMN |
|---|---|---|
| Founded | N/A | 2020 |
| Country | Canada | United States |
| Employees | N/A | 48 |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 914.1M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | CRON | EVMN |
|---|---|---|
| Price | $2.59 | $24.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $43.88 |
| AVG Volume (30 Days) | ★ 1.8M | 251.0K |
| Earning Date | 05-11-2026 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $146,587,000.00 | N/A |
| Revenue This Year | $26.34 | N/A |
| Revenue Next Year | $15.53 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 24.63 | N/A |
| 52 Week Low | $1.81 | $13.89 |
| 52 Week High | $3.43 | $33.20 |
Technical Indicators
Market Signals| Indicator | CRON | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 47.55 | 44.62 |
| Support Level | $2.45 | $21.14 |
| Resistance Level | $2.73 | $25.50 |
| Average True Range (ATR) | 0.14 | 1.80 |
| MACD | -0.00 | -0.32 |
| Stochastic Oscillator | 9.46 | 13.16 |
Price Performance
Historical ComparisonAbout CRON Cronos Group Inc.
Cronos Group Inc headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the U.S., the company has an option to acquire 5.9% of U.S. multistate operator PharmaCann on a fully diluted basis upon easing of federal prohibition.
About EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.